$0.81
+0.06 (+8.20%)
Open$0.77
Previous Close$0.75
Day High$0.84
Day Low$0.76
52W High$35.46
52W Low$25.44
Volume—
Avg Volume287.0K
Market Cap175.69M
P/E Ratio39.70
EPS$0.70
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+4,354.7% upside
Current
$0.81
$0.81
Target
$36.15
$36.15
$26.32
$36.15 avg
$48.95
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 59.14M | 52.95M | 62.98M |
| Net Income | 4.93M | 4.47M | 5.16M |
| Profit Margin | 8.3% | 8.4% | 8.2% |
| EBITDA | 5.59M | 4.86M | 6.72M |
| Free Cash Flow | 3.58M | 3.18M | 3.67M |
| Rev Growth | +23.4% | +5.7% | +6.5% |
| Debt/Equity | 0.46 | 0.42 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |